Severe Asthma Spotlight-Evolving paradigms of treatment selection in severe asthma

Video Transcription

Video Summary

In summary, the selection of biologics for asthma patients is a complex decision that is guided by factors such as biomarkers, comorbidities, preferences, and response to previous therapies. Biomarkers like eosinophils, exhaled nitric oxide, and IgE levels can help determine the type of inflammation present in the asthma patient. Comorbidities such as nasal polyps, atopic dermatitis, COPD, and urticaria can also influence the selection of biologics. Additionally, patient preferences and factors like pregnancy and adherence can be taken into account. It is important to note that there are currently no head-to-head comparative studies of biologics, so making decisions is challenging and requires a personalized approach. The choice of biologic depends on the phenotype and characteristics of the individual patient. For patients with high eosinophils, anti-IL-5 therapies like mepalizumab and benralizumab may be effective. For patients with allergic inflammation, omalizumab may be appropriate. Dupilumab can be considered for patients with mixed type 2 inflammation, and tesepilumab is an option for patients with severe asthma regardless of type 2 status. Ultimately, the selection of biologics should be based on a multidisciplinary approach, taking into account the patient's characteristics, preferences, and treatment goals.

Meta Tag

Category Allergy and Airway

Speaker Diego Maselli Caceres, MD, FCCP

Speaker Sandhya Khurana, MD, FCCP

Speaker Linda Rogers, MD, FCCP

Speaker Dharani Kumari Narendra, MD

Keywords

biologics

asthma patients

biomarkers

comorbidities

preferences

response to previous therapies

eosinophils

exhaled nitric oxide

IgE levels

personalized approach